multiple sclerosis

10 More Newly Approved Drugs
10 More Newly Approved DrugsWhat you need to know about the the 10 newest FDA drug approvals.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
Copay assistance programs: Managed care pros and consDo copay assistance program offer a long-term solution for patients? Experts weigh in.
FDA approves Zinbryta to treat multiple sclerosisFDA recently approved daclizumab (Zinbryta, Biogen and AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS).
Electronic prior authorization and payers: Lessons from BCBSTwo presenters at the AMCP 2016 conference examine a Blue Cross and Blue Shield of Michigan pilot project to leverage technology for its medical specialty drug management program. Here are the lessons learned.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
Shaping specialty pharmacy’s future: 4 perspectivesAt AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.
MS drugs make major advancementsThere is new hope for patients with multiple sclerosis (MS) after positive data on Gilenya and the investigational drug ocrelizumab was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.
MS drug linked to rare brain infectionFDA is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS).
Two cases of rare brain infection seen with MS drugTwo patients taking the multiple sclerosis drug fingolimod (Gilenya) developed progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection, FDA reported.